Cargando…

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Emily M. J., Aponte-Collazo, Lucas J., Pathmasiri, Wimal, Rushing, Blake R., Barker, Natalie K., Partridge, Megan C., Li, Yuan-Yuan, White, Cody A., Greer, Yoshimi E., Herring, Laura E., Lipkowitz, Stanley, Sumner, Susan C. J., Iwanowicz, Edwin J., Graves, Lee M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103842/
https://www.ncbi.nlm.nih.gov/pubmed/37063293
http://dx.doi.org/10.3389/fphar.2023.1136317
_version_ 1785025934734131200
author Fennell, Emily M. J.
Aponte-Collazo, Lucas J.
Pathmasiri, Wimal
Rushing, Blake R.
Barker, Natalie K.
Partridge, Megan C.
Li, Yuan-Yuan
White, Cody A.
Greer, Yoshimi E.
Herring, Laura E.
Lipkowitz, Stanley
Sumner, Susan C. J.
Iwanowicz, Edwin J.
Graves, Lee M.
author_facet Fennell, Emily M. J.
Aponte-Collazo, Lucas J.
Pathmasiri, Wimal
Rushing, Blake R.
Barker, Natalie K.
Partridge, Megan C.
Li, Yuan-Yuan
White, Cody A.
Greer, Yoshimi E.
Herring, Laura E.
Lipkowitz, Stanley
Sumner, Susan C. J.
Iwanowicz, Edwin J.
Graves, Lee M.
author_sort Fennell, Emily M. J.
collection PubMed
description ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes following ClpP activation, the exact mechanism by which ClpP activation leads to broad anti-cancer activity has yet to be fully elucidated. In this study, we utilized a multi-omics approach to identify the ClpP-dependent proteomic, transcriptomic, and metabolomic changes resulting from ONC201 or the TR compound TR-57 in triple-negative breast cancer cells. Applying mass spectrometry-based methods of proteomics and metabolomics, we identified ∼8,000 proteins and 588 metabolites, respectively. From proteomics data, 113 (ONC201) and 191 (TR-57) proteins significantly increased and 572 (ONC201) and 686 (TR-57) proteins significantly decreased in this study. Gene ontological (GO) analysis revealed strong similarities between proteins up- or downregulated by ONC201 or TR-57 treatment. Notably, this included the downregulation of many mitochondrial processes and proteins, including mitochondrial translation and mitochondrial matrix proteins. We performed a large-scale transcriptomic analysis of WT SUM159 cells, identifying ∼7,700 transcripts (746 and 1,100 significantly increasing, 795 and 1,013 significantly decreasing in ONC201 and TR-57 treated cells, respectively). Less than 21% of these genes were affected by these compounds in ClpP null cells. GO analysis of these data demonstrated additional similarity of response to ONC201 and TR-57, including a decrease in transcripts related to the mitochondrial inner membrane and matrix, cell cycle, and nucleus, and increases in other nuclear transcripts and transcripts related to metal-ion binding. Comparison of response between both compounds demonstrated a highly similar response in all -omics datasets. Analysis of metabolites also revealed significant similarities between ONC201 and TR-57 with increases in α-ketoglutarate and 2-hydroxyglutaric acid and decreased ureidosuccinic acid, L-ascorbic acid, L-serine, and cytidine observed following ClpP activation in TNBC cells. Further analysis identified multiple pathways that were specifically impacted by ClpP activation, including ATF4 activation, heme biosynthesis, and the citrulline/urea cycle. In summary the results of our studies demonstrate that ONC201 and TR-57 induce highly similar and broad effects against multiple mitochondrial processes required for cell proliferation.
format Online
Article
Text
id pubmed-10103842
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101038422023-04-15 Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer Fennell, Emily M. J. Aponte-Collazo, Lucas J. Pathmasiri, Wimal Rushing, Blake R. Barker, Natalie K. Partridge, Megan C. Li, Yuan-Yuan White, Cody A. Greer, Yoshimi E. Herring, Laura E. Lipkowitz, Stanley Sumner, Susan C. J. Iwanowicz, Edwin J. Graves, Lee M. Front Pharmacol Pharmacology ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes following ClpP activation, the exact mechanism by which ClpP activation leads to broad anti-cancer activity has yet to be fully elucidated. In this study, we utilized a multi-omics approach to identify the ClpP-dependent proteomic, transcriptomic, and metabolomic changes resulting from ONC201 or the TR compound TR-57 in triple-negative breast cancer cells. Applying mass spectrometry-based methods of proteomics and metabolomics, we identified ∼8,000 proteins and 588 metabolites, respectively. From proteomics data, 113 (ONC201) and 191 (TR-57) proteins significantly increased and 572 (ONC201) and 686 (TR-57) proteins significantly decreased in this study. Gene ontological (GO) analysis revealed strong similarities between proteins up- or downregulated by ONC201 or TR-57 treatment. Notably, this included the downregulation of many mitochondrial processes and proteins, including mitochondrial translation and mitochondrial matrix proteins. We performed a large-scale transcriptomic analysis of WT SUM159 cells, identifying ∼7,700 transcripts (746 and 1,100 significantly increasing, 795 and 1,013 significantly decreasing in ONC201 and TR-57 treated cells, respectively). Less than 21% of these genes were affected by these compounds in ClpP null cells. GO analysis of these data demonstrated additional similarity of response to ONC201 and TR-57, including a decrease in transcripts related to the mitochondrial inner membrane and matrix, cell cycle, and nucleus, and increases in other nuclear transcripts and transcripts related to metal-ion binding. Comparison of response between both compounds demonstrated a highly similar response in all -omics datasets. Analysis of metabolites also revealed significant similarities between ONC201 and TR-57 with increases in α-ketoglutarate and 2-hydroxyglutaric acid and decreased ureidosuccinic acid, L-ascorbic acid, L-serine, and cytidine observed following ClpP activation in TNBC cells. Further analysis identified multiple pathways that were specifically impacted by ClpP activation, including ATF4 activation, heme biosynthesis, and the citrulline/urea cycle. In summary the results of our studies demonstrate that ONC201 and TR-57 induce highly similar and broad effects against multiple mitochondrial processes required for cell proliferation. Frontiers Media S.A. 2023-03-31 /pmc/articles/PMC10103842/ /pubmed/37063293 http://dx.doi.org/10.3389/fphar.2023.1136317 Text en Copyright © 2023 Fennell, Aponte-Collazo, Pathmasiri, Rushing, Barker, Partridge, Li, White, Greer, Herring, Lipkowitz, Sumner, Iwanowicz and Graves. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fennell, Emily M. J.
Aponte-Collazo, Lucas J.
Pathmasiri, Wimal
Rushing, Blake R.
Barker, Natalie K.
Partridge, Megan C.
Li, Yuan-Yuan
White, Cody A.
Greer, Yoshimi E.
Herring, Laura E.
Lipkowitz, Stanley
Sumner, Susan C. J.
Iwanowicz, Edwin J.
Graves, Lee M.
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title_full Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title_fullStr Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title_full_unstemmed Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title_short Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
title_sort multi-omics analyses reveal clpp activators disrupt essential mitochondrial pathways in triple-negative breast cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103842/
https://www.ncbi.nlm.nih.gov/pubmed/37063293
http://dx.doi.org/10.3389/fphar.2023.1136317
work_keys_str_mv AT fennellemilymj multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT apontecollazolucasj multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT pathmasiriwimal multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT rushingblaker multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT barkernataliek multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT partridgemeganc multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT liyuanyuan multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT whitecodya multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT greeryoshimie multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT herringlaurae multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT lipkowitzstanley multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT sumnersusancj multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT iwanowiczedwinj multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer
AT gravesleem multiomicsanalysesrevealclppactivatorsdisruptessentialmitochondrialpathwaysintriplenegativebreastcancer